Innate Pharma SA Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Mar 14, 2024 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
TL;DR
Innate Pharma SA filed a routine 6-K, no major news.
AI Summary
On March 14, 2024, Innate Pharma SA filed a Form 6-K. This report is for a foreign private issuer and does not contain specific financial figures or operational updates beyond confirming its filing status. The company is based in Marseille, France, and operates in the biological products sector.
Why It Matters
This filing indicates Innate Pharma SA is meeting its reporting obligations as a foreign private issuer, which is standard procedure for companies listed on US exchanges.
Risk Assessment
Risk Level: low — This filing is a standard procedural report for a foreign private issuer and does not contain new material information.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- 001-39084 (company) — SEC File Number
- March 14, 2024 (date) — Filing Date
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to report information that they have made or are required to make public in their home country, or that they have submitted or are required to submit to a stock exchange.
What is Innate Pharma SA's primary business sector?
Innate Pharma SA operates in the Biological Products (no diagnostic substances) sector, SIC code 2836.
Where is Innate Pharma SA headquartered?
Innate Pharma SA is headquartered in Marseille, France.
Does this 6-K filing contain specific financial results?
No, this Form 6-K filing does not appear to contain specific financial results or operational updates; it primarily serves as a notification of its reporting status.
What is the SEC file number for Innate Pharma SA?
The SEC file number for Innate Pharma SA is 001-39084.
Filing Stats: 205 words · 1 min read · ~1 pages · Grade level 10.2 · Accepted 2024-03-14 07:00:14
Filing Documents
- a6k-iphx240312.htm (6-K) — 9KB
- exhibit991-240312.htm (EX-99.1) — 15KB
- 0001598599-24-000010.txt ( ) — 26KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date March 14, 2024 By s HERVE BRAILLY Name Herv Brailly Title Chairman of the Executive Board and Chief Executive